Dr. Groman's research program is aimed at understanding the neurobiology and neurodevelopmental mechanisms of decision making to identify biological targets that could be manipulated to prevent and treat mental illness. She received her Ph.D. in 2013 from the Department of Psychology at the University of California, Los Angeles where she trained under Dr. J. David Jentsch and Dr. Edythe London. Her work integrated neuroimaging, behavioral, pharmacological and ex vivo approaches to provide the first evidence that chronic exposure to methamphetamine resulted in the neural and behavioral alterations that had been previously observed in substance-dependent individuals. Her work was recognized by several awards, including a predoctoral NIH NRSA fellowship, the UCLA Brain Research Institute Award and the Joseph A. Gengerelli Distinguished Dissertation Award. She accepted a post-doctoral position in the Department of Psychiatry at Yale University where she trained under Dr. Jane Taylor in studies investigating the biobehavioral mechanisms of addiction.
In 2016 Dr. Groman was promoted to Associate Research Scientists at Yale University where her work has focused on understanding the neural circuits of decision-making and addiction. She integrates computational approaches with neuroimaging, proteomics, and drug self-administration in rodents to provide a translational platform for understanding the biological and neurodevelopmental mechanisms of addiction vulnerability. The Groman Lab will be moving to the Department of Neuroscience at the University of Minnesota in January 2021 and will be a part of the Medical Discovery Team on Addiction.